CN114656531B - 一种具有抗氧化活性的六肽及其应用 - Google Patents
一种具有抗氧化活性的六肽及其应用 Download PDFInfo
- Publication number
- CN114656531B CN114656531B CN202210213143.5A CN202210213143A CN114656531B CN 114656531 B CN114656531 B CN 114656531B CN 202210213143 A CN202210213143 A CN 202210213143A CN 114656531 B CN114656531 B CN 114656531B
- Authority
- CN
- China
- Prior art keywords
- hexapeptide
- antioxidant activity
- antioxidant
- cells
- leucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 38
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 16
- 235000013376 functional food Nutrition 0.000 claims abstract description 6
- 238000010532 solid phase synthesis reaction Methods 0.000 claims abstract description 6
- 230000001681 protective effect Effects 0.000 claims abstract description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims 3
- 230000004792 oxidative damage Effects 0.000 abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- 125000000539 amino acid group Chemical group 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 13
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 10
- 229940118019 malondialdehyde Drugs 0.000 description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003606 umbilical vein Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 101800000068 Antioxidant peptide Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000008810 intracellular oxidative stress Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/90—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in food processing or handling, e.g. food conservation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种具有抗氧化活性的六肽及其应用。所述的多肽包含6个氨基酸残基,分子量为772.93g/mol,理论等电点为7.0,氨基酸序列为:色氨酸‑缬氨酸‑亮氨酸‑天冬氨酸‑赖氨酸‑亮氨酸。本发明所述的六肽来源于食用酵母酶解产物,可通过固相合成制备。本发明的多肽具有良好的抗氧化活性,对DPPH清除的EC50值为1.20mg/mL,且对细胞氧化损伤有保护作用,可用于抗氧化功能食品的开发与制备,具有良好的应用前景。
Description
技术领域
本发明属于功能食品及生物医药领域,特别涉及一种具有抗氧化活性的六肽及其应用。
背景技术
活性氧(ROS)广泛存在于生物体细胞、组织中,具有信号传导、维持内环境稳定等重要的生理作用。然而,ROS积累过多会引起机体产生氧化应激,造成细胞内生物活性大分子的氧化损伤,引发糖尿病、高血压、心血管疾病等慢性疾病。除此以外,氧化应激也是产生衰老的重要原因之一。
抗氧化剂可以减缓氧化应激带来的危害。食物是抗氧化剂的重要来源,世界卫生组织早已认识到抗氧化对健康的重要作用,一直主张在世界范围内增加饮食中抗氧化剂。与常用的抗氧化剂如BHT、BHA等相比,抗氧化肽具有分子量小、结构简单、活性强、易于吸收及无毒害等优点。
因此,从食物中研究并获得具有无毒副作用的新抗氧化肽,有广阔的发展前景和迫切需求。
发明内容
本发明的首要目的在于克服现有技术的缺点与不足,提供一种具有抗氧化活性的六肽。所述的六肽来源于天然产物,是食用酵母酶解产物经LC-MS/MS鉴定、筛选得到,研究发现其具有良好的抗氧化活性。
本发明的另一目的在于提供上述具有抗氧化活性的六肽的应用。
本发明的目的通过下述技术方案实现:
一种具有抗氧化活性的六肽,其氨基酸序列为色氨酸-缬氨酸-亮氨酸-天冬氨酸-赖氨酸-亮氨酸(Trp-Val-Leu-Asp-Lys-Leu)。
所述的具有抗氧化活性的六肽可通过本领域常规技术手段制备得到,例如通过固相合成制备。
上述具有抗氧化活性的六肽在制备抗氧化剂中的应用。
上述具有抗氧化活性的六肽在制备抗氧化功能食品中的应用。
上述具有抗氧化活性的六肽在制备血管内皮细胞保护药物中的应用。
一种抗氧化剂,含有所述的具有抗氧化活性的六肽。
一种抗氧化功能食品,含有所述的具有抗氧化活性的六肽。
一种血管内皮细胞保护药物,含有所述的具有抗氧化活性的六肽。
本发明相对于现有技术具有如下的优点及效果:
1.本发明的六肽具有良好的抗氧化活性,其对DPPH清除的半最大效应浓度EC50为1.20mg/mL。
2.本发明的六肽是一种小分子多肽,理论等电点为7.0,分子量为772.93g/mol,结构易于调控,容易合成、修饰、以得到更好的活力,具有明显的应用潜力。
3.本发明的六肽筛选自食用酵母的酶解产物,来源于酿酒酵母(Saccharomycescerevisiae(strain ATCC 204508/S288c))的内源蛋白质:延伸因子1-α(蛋白质登录号:P02994)。食用酵母被列入FDA发布的“一般认为安全”(GRAS)食品配料,安全性高。
附图说明
图1是固相合成六肽WVLDKL色谱图。
图2是固相合成六肽WVLDKL质谱图。
图3是不同浓度六肽WVLDKL对DPPH清除活性结果分析图。
图4是不同浓度六肽WVLDKL还原力结果分析图。
图5是阳性对照GSH还原力分析图。
图6是六肽WVLDKL对人脐静脉内皮细胞增殖影响结果分析图;其中,**和*分别表示样品组与氧化损伤组相比差异极显著(p<0.01)和差异显著(p<0.05)。
图7是六肽WVLDKL对人脐静脉内皮细胞中MDA含量影响结果分析图;其中,**和*分别表示样品组与氧化损伤组相比差异极显著(p<0.01)和差异显著(p<0.05)。
图8是六肽WVLDKL对人脐静脉内皮细胞中SOD活性影响结果分析图;其中,**和*分别表示样品组与氧化损伤组相比差异极显著(p<0.01)和差异显著(p<0.05)。
具体实施方式
下面结合实施例及附图对本发明作进一步详细的描述,但本发明的实施方式不限于此。
实施例1
采用Fmoc固相合成法人工合成制备序列为色氨酸-缬氨酸-亮氨酸-天冬氨酸-赖氨酸-亮氨酸(Trp-Val-Leu-Asp-Lys-Leu)的六肽。根据六肽的氨基酸残基组成,以氨基端具有芴甲氧羰酰基(Fmoc-)保护基团的各种氨基酸(Fmoc-Trp、Fmoc-Val、Fmoc-Leu、Fmoc-Asp、Fmoc-Lys)为原料,将Fmoc-Leu的羧基以共价键与高分子树脂(Wang树脂)相连;加入含20%(v/v)的哌啶的二甲基甲酰胺(DMF),反应0.5h脱去氨基保护基Fmoc-;加入过量的Fmoc-Lys,以羟基苯并三唑为缩合剂,在30℃下反应2h,使得Fmoc-Lys的羧基与树脂上Leu的活性氨基缩合;重复脱保护基和缩合反应,依次连接余下的其它氨基酸后,将六肽从树脂上裂解,经C18柱分离纯化,冷冻干燥,制得该六肽。通过液相色谱图(图1)分析可知,该法合成的本发明所述小分子肽,纯度为99.29%。液相色谱-质谱图(图2)证明合成的该六肽为Trp-Val-Leu-Asp-Lys-Leu。
实施例2
DPPH以乙醇配制(0.1mmol/L)。以去离子水将本发明小分子肽分别配制成为0.5~5mg/mL浓度溶液。取六肽溶液0.15mL加DPPH 0.15mL,25℃避光静置1h,测定517nm处的吸光值(Am);取样品0.15mL加入无水乙醇0.15mL,25℃避光静置1h,其吸光值Ax作为背景从Am中扣除;以去离子水作为对照组,吸光值标记为An。按公式(1)计算DPPH自由基清除率(SA)。
从图3可知,本发明所述六肽对DPPH清除的EC50值为1.20mg/mL,具有良好的抗氧化活性。
实施例3
用0.2mol/L的PBS缓冲液(pH 6.6)配制所有样品。以PBS为空白对照,以GSH(0.02-0.16mg/mL)为阳性对照。分别将1.0mL不同质量浓度(0.5mg/mL、1.0mg/mL、1.5mg/mL、2.0mg/mL、2.5mg/mL)的所述六肽加入1.0mL 1%浓度的K3[Fe(CN)6],于50℃水浴反应30min,用三氯乙酸(10%,2mL)终止反应。加入FeCl3(0.1%,1.25mL)静置20min。反应液在700nm处的吸光值指示样品的还原力。
由图4和图5可见,在测定范围内,还原力随样品浓度升高而增加,线性关系良好。当A700=0.5时,多肽浓度为1.73mg/mL说明本发明所述六肽具有较强的还原力。
实施例4
培养人脐静脉内皮细胞系EA.hy 926细胞,细胞培养液由90%DMEM培养液(NaHCO31.5g/L,pH 7.0)、10%南美血源胎牛血清和1%青霉素/链霉素双抗配制。取细胞以1.0e5cells/mL密度接入T25细胞培养瓶,置于37℃,5%CO2培养箱内培养,每2天换一次培养液,每4天传代一次。取3~5代细胞,培养至对数期后,用胰酶消化,以1.0e5 cells/mL密度加入6孔板,每孔1mL,每组4个复孔。待培养至细胞长满孔底80%以上时,吸弃原培养液换以1mL含六肽(323μM或647μM)的无血清培养液培养对细胞预处理24h,吸弃细胞培养液。以抗氧化剂谷胱甘肽(GSH)(浓度为1.63μM)作为阳性对照。
之后在各组中加入200μL H2O2(250μM)的无血清培养液诱导细胞产生氧化损伤,继续培养24h后取一组样品以MTT法测定细胞存活率。另一组样品测定细胞内MDA和SOD指标。
MTT法具体操作为:于24h和48h时,每孔加入20μL MTT(5mg/mL),培养4h,吸弃孔中液体,加入150μL DMSO轻微震荡10min,用酶标仪测定570nm处吸光值。以无细胞培养液,加入等量MTT,4h后吸弃培养液,加入150μL DMSO作为调零孔。细胞存活率按公式(2)计算。
细胞存活率(%)=实验组吸光值/对照组吸光值 公式(2)
MDA和SOD测定操作为:消化、离心保留沉淀,并用无菌PBS缓冲液(4℃)对细胞沉淀进行清洗,重复两次,利用液氮对细胞进行反复冻融以使细胞破碎。采用总蛋白试剂盒(南京建成生物工程研究所,产品号:A045-4-2)测定细胞内总蛋白,采用丙二醛(MDA)试剂盒(南京建成生物工程研究所,产品号:A003-1-2)测定细胞内MDA的含量,采用SOD试剂盒南京建成生物工程研究所,产品号:A001-3-2)测定细胞内SOD的活性。如图6所示,250μM的H2O2处理可以产生氧化损伤,显著抑制EA.hy 926细胞的增殖,损伤模型组的细胞存活率为47.80±4.62%。低、高剂量的六肽处理后细胞的存活率分别为53.65±4.57%和58.47±5.28%。与损伤模型组相比,本发明所述六肽可极显著提高细胞存活率,对细胞氧化损伤的保护作用极显著(p<0.01)。
由图7可以发现,与对照组相比,H2O2处理的氧化损伤模型细胞内MDA含量由3.09±0.65μM/mgprot(毫克蛋白质)升高至11.09±1.38μM/mgprot。本发明所述六肽低剂量和高剂量处理后细胞内MDA测定值分别为10.09±1.03μM/mgprot和8.18±0.51μM/mgprot(p<0.01),表示本发明所述六肽能极显著减少细胞内MDA的生成。MDA是细胞内氧化应激标志物,其含量的降低表示本发明所述六肽能保护内皮细胞抵抗由H2O2诱导的氧化损伤。
由图8可以发现,与对照组相比,H2O2处理的氧化损伤模型细胞内SOD活性急剧下降,由44.08±1.97U/mgprot降至23.62±2.23U/mgprot(p<0.01)。本发明所述六肽在低、高浓度处理后,细胞内SOD活性分别提升至26.87±2.62U/mgprot和28.85±3.01U/mgprot(p<0.01)。本发明所述六肽能极显著提升血管内皮细胞内抗氧化酶SOD的活性。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (8)
1.一种具有抗氧化活性的六肽,其特征在于:
其氨基酸序列为色氨酸-缬氨酸-亮氨酸-天冬氨酸-赖氨酸-亮氨酸。
2.根据权利要求1所述的具有抗氧化活性的六肽,其特征在于:
所述的具有抗氧化活性的六肽通过固相合成制备得到。
3.权利要求1或2所述的具有抗氧化活性的六肽在制备抗氧化剂中的应用。
4.权利要求1或2所述的具有抗氧化活性的六肽在制备抗氧化功能食品中的应用。
5.权利要求1或2所述的具有抗氧化活性的六肽在制备血管内皮细胞保护药物中的应用。
6.一种抗氧化剂,其特征在于:含有权利要求1或2所述的具有抗氧化活性的六肽。
7.一种抗氧化功能食品,其特征在于:含有权利要求1或2所述的具有抗氧化活性的六肽。
8.一种血管内皮细胞保护药物,其特征在于:含有权利要求1或2所述的具有抗氧化活性的六肽。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210213143.5A CN114656531B (zh) | 2022-03-04 | 2022-03-04 | 一种具有抗氧化活性的六肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210213143.5A CN114656531B (zh) | 2022-03-04 | 2022-03-04 | 一种具有抗氧化活性的六肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114656531A CN114656531A (zh) | 2022-06-24 |
CN114656531B true CN114656531B (zh) | 2023-05-23 |
Family
ID=82028109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210213143.5A Active CN114656531B (zh) | 2022-03-04 | 2022-03-04 | 一种具有抗氧化活性的六肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114656531B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102286591A (zh) * | 2011-09-15 | 2011-12-21 | 华南理工大学 | 一种酵母来源活性多肽的制备方法 |
CN111647072A (zh) * | 2020-06-18 | 2020-09-11 | 天津商业大学 | 一种抗氧化肽及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11028402B2 (en) * | 2018-04-06 | 2021-06-08 | Wisconsin Alumni Research Foundation | Polypeptide and yeast cell compositions and methods of using the same |
-
2022
- 2022-03-04 CN CN202210213143.5A patent/CN114656531B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102286591A (zh) * | 2011-09-15 | 2011-12-21 | 华南理工大学 | 一种酵母来源活性多肽的制备方法 |
CN111647072A (zh) * | 2020-06-18 | 2020-09-11 | 天津商业大学 | 一种抗氧化肽及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
He Ni,et al..Isolation and identification of an Angiotensin-I converting enzyme inhibitory peptide from yeast(saccharomyces cerevisiae).《Current Analytical Chemistry》.2012,第第8卷卷第180-185页. * |
付豪 等.酵母多肽的分离纯化及其化妆品功效研究.《湖北农业科学》.2020,第59卷(第7期),第184-187页. * |
Also Published As
Publication number | Publication date |
---|---|
CN114656531A (zh) | 2022-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111647072B (zh) | 一种抗氧化肽及其制备方法和应用 | |
CN113121557B (zh) | 海洋真菌来源的杂萜化合物及其在制备抗炎药物中的应用 | |
CN117247430B (zh) | 一种玉米抗氧化肽及其制备方法与应用 | |
CN110551764B (zh) | 一种提高功能性红曲开环洛伐他汀含量的培养基及发酵方法 | |
CN114656531B (zh) | 一种具有抗氧化活性的六肽及其应用 | |
CN116514912B (zh) | 抗皮肤氧化损伤的草菇多肽及其应用 | |
CN113208956B (zh) | 一种具有抗光老化功效的大豆发酵液及其制备方法与应用 | |
CN114657162B (zh) | 一种具有血管内皮细胞保护功能的抗氧化五肽及其应用 | |
CN116621934B (zh) | 来源于草菇的抗皮肤氧化和抑制氧化应激的多肽及其应用 | |
CN113308378B (zh) | 高产麦角硫因的灵芝菌株及其应用 | |
CN114907445B (zh) | 一种高抗氧化活性富硒肽及其应用 | |
CN111978370B (zh) | 一种奇亚籽抗氧化肽及其制备方法与应用 | |
CN115124591A (zh) | 钝顶螺旋藻藻蓝蛋白血管紧张素转化酶抑制肽及其制备方法和应用 | |
CN111116712B (zh) | 一种具有ace抑制活性的六肽及其应用 | |
CN112521446B (zh) | 一种ace抑制肽及其用途 | |
CN111087446B (zh) | 一种抑制血管紧张素转换酶的十肽及其应用 | |
CN114073659B (zh) | 一种泛喜马拉雅地区鸡爪谷酒酒糟来源类干酪乳杆菌的发酵产物制备及其应用 | |
CN114989248A (zh) | 一种具有抗炎抗氧化活性的忧遁草多肽及其制备方法和应用 | |
CN109096368B (zh) | 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用 | |
CN112028970A (zh) | 一种牡丹籽粕ace抑制肽及其制备方法与应用 | |
CN111004308B (zh) | 一种抑制血管紧张素转换酶的七肽及其应用 | |
CN114081862B (zh) | 一种泛喜马拉雅地区青稞酒酒曲来源的酿酒酵母发酵产物制备及其应用 | |
CN116284301B (zh) | 一种抗氧化多肽及其应用 | |
CN114573664B (zh) | 一种忧遁草抗氧化十三肽及其制备方法和应用 | |
CN112980901B (zh) | 一种利用槐耳、槐耳及云芝发酵培养制备甲酰苯胺类化合物的方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |